NCT07046715

Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State

An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

This study is to compare pharmacokinetics and safety profiles of single-administration of DA-5222 and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects in fed state

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DA-5222	single dose administration (DA-5222 one tablet once a day)
DRUG	DA-5222-R1	single dose administration (DA-5222-R1 one tablet once a day)
DRUG	DA-5222-R2	single dose administration (DA-5222-R2 one tablet once a day)
DRUG	DA-5222-R3	single dose administration (DA-5222-R3 one tablet once a day)

Timeline

• Start date: 2025-07-07
• Primary completion: 2025-08-19
• Completion: 2025-08-19
• First posted: 2025-07-01
• Last updated: 2025-11-17

Locations

1 site across 1 country: South Korea